Ekso Bionics(TM) to Present at the 9th Annual JMP Securities Healthcare Conference
June 18 2014 - 7:00AM
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, announced today that Nathan Harding, chief executive
officer and co-founder will present a corporate update at the 9th
Annual JMP Securities Healthcare Conference on Tuesday, June 24,
2014 at 2:30 p.m. EDT in New York City. A live
demonstration of their bionic exoskeleton technology will also be
provided.
Ekso Bionics designs, develops, and commercializes exoskeletons,
or wearable robots, which have a variety of applications in the
medical, military, industrial, and consumer markets. Exoskeletons
are ready-to-wear, battery-powered robots that are strapped over
the user's clothing, enabling individuals to achieve mobility,
strength, and endurance not otherwise possible. Ekso Bionics' lead
product, EksoTM, is a wearable bionic suit that enables individuals
with any amount of lower extremity weakness to stand up and walk
over ground. Ekso is forging a new frontier in rehabilitation for
people living with the consequences of stroke, spinal cord injury
and other neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of
robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on
the OTC QB under the symbol EKSO. To learn more about Ekso Bionics
please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not
meant to predict or guarantee actual results, performance, events
or circumstances and may not be realized because they are based
upon the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time and
resources associated with the development of our products and
related insufficient cash flows and resulting illiquidity, the
Company's inability to expand the Company's business, significant
government regulation of medical devices and the healthcare
industry, lack of product diversification, volatility in the price
of the Company's raw materials, existing or increased competition,
results of arbitration and litigation, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including, the Company's Current Report on Form 8-K/A
filed on March 31, 2014 and the Company's latest Form 10-Q filed on
May 13, 2014. The Company does not undertake to update these
forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024